EPM
ALNY icon

Elm Partners Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Elm Partners Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,043
Closed -$646K – 162
2026
Q1 		$646K Buy
2,043
+35
+2% +$11.9K 0.03% 82
2025
Q4 		$798K Buy
+2,008
New +$889K 0.04% 79

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elm Partners Management's ALNY Position: Q2 2026 in Review

Elm Partners Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 2,043 shares — an estimated $646K sold.

Elm Partners Management first reported a position in ALNY in Q4 2025 and held it in 2 quarters. The position peaked at $798K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Elm Partners Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Elm Partners Management sold 2,043 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $646K.
  • Elm Partners Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Elm Partners Management's Alnylam Pharmaceuticals position peaked at $798K in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Elm Partners Management's 13F filing for Q2 2026, filed 28 Jul 2026.